The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The combination of the IAP antagonist, tolinapant and hypomethylating agents (HMA) is highly synergistic in in vitro models of T-cell lymphoma (TCL).
 
John Manavalan
Research Funding - Astex Pharmaceuticals
 
Ipsita Pal
No Relationships to Disclose
 
Aidan Pursley
No Relationships to Disclose
 
George Ward
Employment - Astex Pharmaceuticals
 
Tomoko Smyth
Employment - Astex Pharmaceuticals
 
Martin Sims
Employment - Astex Pharmaceuticals
 
David Feith
Honoraria - Kymera
Research Funding - AstraZeneca Canada
 
Thomas Loughran
Stock and Other Ownership Interests - Bioniz; DAAN Biotherapeutics; Keystone Nano
Honoraria - Kymera
Consulting or Advisory Role - Bioniz; DAAN Biotherapeutics; Keystone Nano
 
Owen O’Connor
Employment - TG Therapeutics
Leadership - Kymera; Myeloid Therapeutics; nomocan; TG Therapeutics
Stock and Other Ownership Interests - Kymera; Myeloid Therapeutics; TG Therapeutics
Honoraria - Mundipharma
Consulting or Advisory Role - Astex Pharmaceuticals; Mundipharma Research
Research Funding - Astex Pharmaceuticals (Inst); Celgene/Bristol-Myers Squibb (Inst); Merck (Inst); Mundipharma (Inst); Seagen (Inst)
 
Enrica Marchi
Consulting or Advisory Role - Daiichi Sankyo; Kymera; Kyowa Kirin; Myeloid Therapeutics
Research Funding - Astex Pharmaceuticals; Celgene; Merck; NomoCan